vgx-1027
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT00627120)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetOTHER
Unknown
Anti-inflammatory drug, mechanism of action may involve the inhibition of NF-kB and the early transient inhibition of P38 MAP kinase signaling pathways.
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)CC1CC(c2ccccc2)=NO1- Mol. weight
- 205.21 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1320667 ↗
Also known as
- 3-phenyl-4,5-dihydro-5-isoxazole acetic acid
- git27
- (s,r)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid
- vgx-1027
- vgx-1027
- vgx-1027
- vgx-1027
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00760396 | Phase 1 | Sep 1, 2008 | GeneOne Life Science, Shin Nippon Biomedical Laboratories, VGX Pharmaceuticals, LLC |
| NCT00627120 | Phase 1 | Feb 1, 2008 | GeneOne Life Science, Shin Nippon Biomedical Laboratories, VGX Pharmaceuticals, LLC |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GeneOne Life Science | For profit | 2 | 0 | 1 | 2008 |
| Shin Nippon Biomedical Laboratories | For profit | 2 | 0 | 1 | 2008 |
| VGX Pharmaceuticals, LLC | For profit | 2 | 2 | 1 | 2008 |
3 organizations
Page 1 / 1